Climb Bio (CLYM) Share-based Compensation (2020 - 2026)

Climb Bio's Share-based Compensation history runs 7 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• Quarterly Share-based Compensation fell 20.62% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.5 million (up 75.4% YoY) and the FY2025 annual result came in at $11.7 million, up 110.55% from the prior year.
• Share-based Compensation was $1.6 million for Q1 2026 at Climb Bio, down from $7.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $10.2 million in Q3 2025 and bottomed at $313000.0 in Q1 2023.
• A 5-year average of $2.3 million and a median of $1.6 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 418.86% — and 2023, when it plunged 79.69%.
• Climb Bio's Share-based Compensation stood at $1.8 million in 2022, then tumbled by 32.59% to $1.2 million in 2023, then jumped by 37.94% to $1.7 million in 2024, then jumped by 372.74% to $7.8 million in 2025, then plunged by 79.52% to $1.6 million in 2026.
• Business Quant data shows CLYM's Share-based Compensation at $1.6 million in Q1 2026, $7.8 million in Q4 2025, and $10.2 million in Q3 2025.